Price
$2.13
Increased by +0.47%
Dollar Volume
42.59 K
ADR%
4.27
Earnings Report Date (estimate)
Oct 28, 22 (N/A)
Market Cap.
30.69 M
Shares Float
10.96 M
Shares Outstanding
14.41 M
Beta
1.82
Price / Earnings
-1.66
BPR
56.51
20D Range
1.85 2.15
50D Range
1.85 2.19
200D Range
1.76 2.59
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 5, 20 -0.73
Increased by +35.96%
-2.58
Increased by +71.71%
May 6, 20 -0.83
Increased by +55.38%
-2.04
Increased by +59.31%
Feb 18, 20 -0.77
Increased by +57.22%
-0.99
Increased by +22.22%
Nov 6, 19 -0.76
Increased by +61.62%
-1.30
Increased by +41.54%
Aug 1, 19 -1.14
Increased by +57.78%
-1.86
Increased by +38.71%
May 8, 19 -1.86
Increased by +48.33%
-1.98
Increased by +6.06%
Feb 27, 19 -1.80
Increased by +70.59%
-2.52
Increased by +28.57%
Nov 14, 18 -1.98
Increased by +99.92%
-3.42
Increased by +42.11%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-2.33 M
Increased by +50.49%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-3.15 M
Increased by +34.90%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-3.27 M
Increased by +20.20%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-5.68 M
Decreased by -10.75%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-4.71 M
Decreased by -136.66%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-4.83 M
Decreased by -271.27%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-4.10 M
Decreased by -210.61%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-5.13 M
Decreased by -318.03%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.